Press releases

6 December, 2022

Abliva initiates the global FALCON study with lead candidate KL1333

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe mitochondrial diseases, today announced the start of the company’s global ...

22 November, 2022

Regulatory

Abliva AB Interim Report January – September 2022

Additional regulatory approvals to start the FALCON study with KL1333 ⎮ World Mitochondrial Disease Week raised awareness of mitochondrial diseases

16 September, 2022

Abliva to participate in World Mitochondrial Disease Week 2022

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the company will par ...

19 August, 2022

Regulatory

Abliva AB Interim Report January – June 2022

SEK 200 million financing secured ⎮ KL1333 study due to start this year ⎮ NV354 is being prepared for clinical studies

29 July, 2022

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 146,547,924, as a result of a preferential rights issue announced by the Board of ...

13 July, 2022

Regulatory

Last day of trading with BTA in Abliva

Abliva AB has carried out a rights issue where the subscription period ended June 27, 2022. The rights issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket) and t ...

30 June, 2022

Regulatory

Amended number of shares and votes in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) today announces that the number of shares and votes in the Company has increased by 506,744,443, as a result of a directed share issue announced by the Board of Dire ...

29 June, 2022

Regulatory

Abliva finishes SEK200M financing round with publication of rights issue outcome

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva”) or the ”Company”) today announces that the new share issue with preferential rights for existing shareholders, announced by the Company on 1 June 2022 (th ...

20 June, 2022

Spots left: Abliva’s Fireside Chat in Lund and Stockholm

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biotech company developing medicines for the treatment of rare and severe primary mitochondrial diseases, invites interested shareholders and inves ...

14 June, 2022

Meet Abliva live: Fireside Chat in Lund and Stockholm

8 June, 2022

Regulatory

Abliva publishes prospectus in connection with fully underwritten rights issue and admission to trading of newly issued shares

The Board of Directors in Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has, in connection with the new issues announced on 31 May, 2022, and the conversion of the Company's convertib ...

1 June, 2022

Regulatory

Abliva decides on a SEK 200 million financing to fund Phase 2/3 study of KL1333 to interim analysis and bring in new global life science and institutional investors

The Board of Directors of Abliva AB (Nasdaq Stockholm: ABLI) (“Abliva” or the “Company”) has approved a directed issue of approximately SEK 150 million to several life science specialist and instituti ...